Develop a platform for cell programming. Program cells to enable biological production of products. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 14% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 2.6× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 23% of them.
Analysts' average target sits 25% below today's price.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $170.2M a year. A small number, but proof the product has real buyers.
A loss of $312.8M against $170.2M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.
The stock trades 25% above the average analyst price target.
On our five-subject report card, DNA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.